Jielun Zhu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Fapon expands one-stop solution for the IVD industry

Fapon’s Shine i8000/9000 CLIA analyzer caters to high-volume clinical testing needs and scales up IVD offering

San diegoUnited statesJielun zhuSandeepk vashistKevin liuScientific meeting clinical lab expoLaboratory medicineAssociation for diagnosticsEditorial articleAnnual scientific meetingClinical labSenior globalGlobal sales directorFapon expands one stop solution for the ivd industry and sets sights on next generation therapeutics selectscienceLia analzyerCancer therapies

Fapon expands one-stop solution for the IVD industry

Fapon’s Shine i8000/9000 CLIA analyzer caters to high-volume clinical testing needs and scales up IVD offering

San diegoUnited statesKevin liuSandeepk vashistJielun zhuLaboratory medicineAssociation for diagnosticsScientific meeting clinical lab expoEditorial articleAnnual scientific meetingClinical labSenior globalGlobal sales directorFapon expands one stop solution for the ivd industry and sets sights on next generation therapeutics selectscienceLia analzyerCancer therapies

I-Mab Biopharma (IMAB) Provides Business Update, Report H1 22 Results

I-Mab Biopharma (IMAB) Provides Business Update, Report H1 22 Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongSouth koreaZheru zhangLin liJingwu zangJielun zhuGenexine neoimmunetechGoldman sachs gao hua securities companyAmerican society of clinical oncologyCompany nasdaqUpdates regarding holding foreign companies accountable actAudit committeeCompany onChina securities regulatory commissionAsia executive team

I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.

United statesHong kongSan diegoEmilie wuZheru zhangJingwu zhang zangAndrew zhuGigi fengJingwu zangJielun zhuWeimin tangYifei zhuWei fuRichard liJohn longCompany nasdaq

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021

Financial results demonstrate strong fundamentals Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab,.

San diegoUnited statesSouth koreaYifei zhuAndrew zhuJingwu zangJielun zhuGenexine neoimmunetechAmerican society of clinical oncologyPrnewswire the company nasdaqFourth china international import expoAmerican society of hematologyAmerican association for cancer researchSinopharm group co5th companyBusiness development